Our products and services are essential components for the research, development and production of new generation medicines as for example vaccines, immuno-oncology therapies, and protein replacement treatments.
Discover our latest initiatives, technology advancements, expansion plans, and our ongoing commitment to research and development of cutting-edge solutions for Cell & Gene Therapies and Nucleic Acids.
Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell based therapies
read moreAnemocyte is excited to announce its participation as an attendee at TIDES USA 2025, taking place from May 19–22, 2025, at the Manchester Grand Hyatt in San Diego, California.
read moreAnemocyte announces its sponsorship and exhibition at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), from May 13–17, 2025.
read moreAnemocyte is excited to announce its participation as an exhibitor at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting, taking place from May 7 to 10 in New Orleans, Louisiana.
read more
The “Anemocyte Run4Life” team—made up of five Anemocyte employees—took part in the 2025 Milano Marathon, choosing to support the Italian Cystic Fibrosis Research Foundation (FFC Ricerca – ETS)through the Rete del Dono fundraising platform.
read moreAnemocyte is pleased to announce the opening of its new company in the United States, Anemocyte Inc., based in Miami, Florida.
read moreAnemocyte is pleased to announce its participation in the Cell & Gene Meeting on the Med 2025, taking place from April 15th to 17th at the Rome Cavalieri in Rome.
read moreAnemocyte is excited to announce its participation in CPHI Japan 2025, taking place from April 9th to 11th at Tokyo Big Sight in Halls East 4, 5, and 6.
read moreThe international BIO-Europe Spring® conference is now in its 19th year and this year will take place in Milan at Allianz MiCo from March 17-19, 2025.
read moreThe symposium will be held in Rimini, Italy, March 17-19, involving all researchers conducting research in the field of rare genetic diseases with the Fondazione Telethon’s support.
read moreAnemocyte is excited to announce its participation in mRNA Leaders Europe, the premier event for RNA-based therapy innovations, taking place in Basel, 4-6 March 2025 at Congress Center Basel, Switzerland.
read morePlasmid manufacturing is evolving. Learn how innovations like automation, continuous processing, and AI are addressing challenges and setting new industry standards at Anemocyte.”
read more
Anemocyte S.r.l. Single Shareholder Private Limited-Liability Company
Via R. Lepetit, 34 21040 Gerenzano (VA) Italy | Ph: +39 02 99372311 – Fax: +39 02 99372313 | Anemocyte Inc. 1221 Brickell Avenue, Suite 1160 Miami FL 33131
VAT number: 12914940155 | Share capital € 530.000,00 fully paid | R.E.A. 276961
